Suspension of trading

ICAD Stock

ICAD

US44934S2068

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 23:00:00 16/07/2025 +03			5-day change	1st Jan Change
3.870 ^USD	+3.75%		-.--%	-

21/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from S&P TMI Index	CI
18/07/25	ICAD, Inc.(NasdaqCM:ICAD) dropped from Russell Microcap Value Benchmark Index	CI

Analysts' recommendations: ICAD

17/04/25	RadNet's iCAD Deal to Expand its Digital Health Services and Geographic Presence, Truist Says	MT
17/04/25	BTIG Research Downgrades iCAD to Neutral From Buy	MT
19/07/23	Lake Street Adjusts Price Target on icad to $5 From $2.50, Maintains Buy Rating	MT
13/04/23	JMP Securities Adjusts iCAD's Price Target to $4 From $7, Keeps Outperform Rating	MT
04/04/23	Oppenheimer Adjusts iCAD Price Target to $4 From $5, Maintains Outperform Rating	MT

More recommendations

iCAD Inc is a United Statesâ€‘based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AIâ€‘driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Stock Market
Stocks
ICAD Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	106M 90.49M 84.66M 77.4M 146M 10.11B 148M 1B 390M 5.08B 396M 388M 16.8B	P/E 2023	-9.35x	P/E 2024	-8.59x
Enterprise Value	88.75M 76.06M 71.15M 65.05M 123M 8.5B 124M 842M 327M 4.27B 333M 326M 14.12B	EV / Sales 2023	1.47x	EV / Sales 2024	1.6x
Free-Float	99.32%	Yield 2023 *	-	Yield 2024	-

08/07/25	ICAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by RadNet, Inc.	AQ
04/06/25	ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD	BU
13/05/25	ICAD Reports Financial Results for First Quarter Ended March 31, 2025	AQ
29/04/25	ICAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft’s Precision Imaging Network (PIN)	AQ
17/04/25	ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD	BU

13/03/23	LA PREMIÈRE ÉTAPE DE L’OPÉRATION CONSISTE EN LA CESSION PAR ICAD…
26/04/21	CAC 40 : Les valeurs à suivre à Paris et en Europe
26/04/21	Les valeurs à suivre à Paris et en Europe (actualisé)
18/10/19	ICAD : annonce l’installation de la solution ProFound AI™ 2D pour la mammographie et pour la tomosynthèse (DBT) 3D au Centre d’Imagerie Paris Nord Sarcelles
25/01/19	Dow Jones Industrial Average : Wall Street attendue en hausse malgré Intel et les doutes sur la croissance

3 years	1.18	4.02
5 years	1.05	12.73
10 years	1.05	21.44

Manager	Title	Age	Since
Dana Brown CEO	Chief Executive Officer	61	10/03/2023
Mark Stolper DFI	Director of Finance/CFO	54	17/07/2025
Dave Katz SEC	Corporate Secretary	-	17/07/2025

ICAD Stock

Stocks

ICAD

US44934S2068

Advanced Medical Equipment & Technology

Valuation: ICAD

Latest news : ICAD

Analysts' recommendations: ICAD

Press Releases: ICAD

News in other languages: ICAD

Quotes and Performance

Course Extremes

Managers and Directors: ICAD

Latest insider transactions

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/17/25 A	Andrew Sassine	Issuer sale	Director	1,553,657	5.8540%
7/17/25 A	Eric Lonnqvist	Issuer sale	Chief Financial Officer	158,488	0.5972%
7/17/25 A	Jonathan Go	Issuer sale	Chief Technology Officer	351,145	1.3231%

	2023	2024
Net sales	17.32M 14.84M 13.88M 12.69M 23.95M 1.66B 24.21M 164M 63.88M 833M 65.02M 63.62M 2.75B	19.61M 16.8M 15.72M 14.37M 27.12M 1.88B 27.41M 186M 72.33M 943M 73.62M 72.03M 3.12B
Net income	-4.85M -4.15M -3.89M -3.55M -6.7M -464M -6.78M -45.98M -17.88M -233M -18.2M -17.8M -771M	-5.62M -4.81M -4.5M -4.12M -7.77M -538M -7.85M -53.28M -20.72M -270M -21.09M -20.63M -893M
Net Debt	-21.21M -18.18M -17M -15.55M -29.34M -2.03B -29.65M -201M -78.24M -1.02B -79.63M -77.91M -3.37B	-16.84M -14.44M -13.5M -12.35M -23.3M -1.61B -23.55M -160M -62.14M -810M -63.24M -61.87M -2.68B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ICAD	+3.75%	-.--%	-.--%	+82.55%	106M
THERMO FISHER SCIENTIFIC, INC.	-0.08%	+7.38%	+25.75%	+16.86%	233B
DANAHER CORPORATION	-1.71%	+6.16%	+1.56%	-15.16%	154B
INTUITIVE SURGICAL, INC.	-1.38%	-4.29%	-21.55%	+30.78%	134B
BOSTON SCIENTIFIC CORPORATION	-2.70%	-4.71%	-53.84%	-2.82%	73B
SIEMENS HEALTHINEERS AG	+0.47%	+3.56%	-15.82%	-11.66%	52.24B
EDWARDS LIFESCIENCES CORPORATION	+0.79%	-0.34%	+10.60%	+20.65%	51.75B
AGILENT TECHNOLOGIES, INC.	-3.50%	+3.35%	+26.14%	+28.40%	44.91B
WATERS CORPORATION	+0.01%	+0.74%	+35.92%	+51.47%	40.35B
GE HEALTHCARE TECHNOLOGIES INC.	-0.84%	+2.51%	-1.37%	+8.42%	33.8B
Average	-0.33%	+1.64%	+0.74%	+20.95%	81.65B
Weighted average by Cap.	-0.65%	+2.77%	+2.10%	+11.77%